Q&A: Bio­Marin com­mer­cial chief Jeff Ajer gears up for biggest drug launch to date — with an­oth­er wait­ing in the wings

Is Bio­Marin’s chief com­mer­cial of­fi­cer ready to get off the com­pa­ny’s roller­coast­er ride of the past few years? Not nec­es­sar­i­ly. As CCO Jeff Ajer says it’s ex­pect­ed at Bio­Marin that “drug de­vel­op­ment does not go in a straight line.”

Al­though right now Bio­Marin’s line seems to be a straight line head­ing up. Last week it post­ed pos­i­tive da­ta for its he­mo­phil­ia A gene ther­a­py Roc­ta­vian, bounc­ing back af­ter a sur­prise FDA CRL in 2020 that re­quest­ed more da­ta. It has al­ready filed for Roc­ta­vian’s ap­proval in Eu­rope and plans to sub­mit to the FDA again in the sec­ond quar­ter. Mean­while, in No­vem­ber, it nabbed an FDA nod for Vox­zo­go, the first ap­proved drug to treat chil­dren with achon­dropla­sia, the most com­mon form of dwarfism, fol­low­ing on a sum­mer ap­proval in Eu­rope.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN